AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

Shots:

• Transgene to receive $10M upfront & $3M preclinical milestones, providing its oncolytic virus expertise with Vaccinia Virus (TK-, RR-) double-deleted backbone and will take care of in-vitro pre-clinical development
• AZ has an option to select 5 oncolytic immunotherapies based on Invir.IO and will be responsible for its in-vivo pre and clinical development with the commercialization of candidates. If AZ exercises its option, Transgene will receive option exercise payment, development & commercial milestones and royalties on sales of each candidate
• Transgene’s Invir.IO utilizes viral vector technology to design therapies for multifunctional oncolytic viruses. Transgene has various pre and clinical -stage vaccines including TG4010, TG4001 & TG1050, TG6002 for NSCLC, HPV+ head and neck cancers & hepatitis B and solid tumors respectively

Click here to read full press release/ article | Ref: BusinessWire| Image: Veolia